Institutional Profile: the National Swedish Academic Drug Discovery &amp; Development Platform at Scilifelab

Arvidsson, Per I.; Sandberg, Kristian; Sakariassen, Kjell S.

doi:10.4155/fsoa-2017-0013

Cited by 3 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Definitively, we believe that these observations call for changes in the management of research in many countries. With regard to academic drug discovery, important efforts have been done, for example in the USA, with the creation of the Academic Drug Discovery Consortium or dynamic maps to develop small molecules or biologics proposed by the National Center for Advancing Translational Sciences [255] , [256] , [257] , in UK [258] , [259] or in Sweden [260] , to mention only a few. Of course, we are all aware that academic drug discovery is challenging and difficult to organize [261] .…”

Section: Preparation For the Next Global Health Crisesmentioning

confidence: 99%

Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises

Singh¹,

Villoutreix²

2021

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Section: Preparation For the Next Global Health Crisesmentioning

confidence: 99%

Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises

Singh¹,

Villoutreix²

2021

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

“…Q You are the Director for Drug Discovery & Development at SciLifeLab [1]. What does that position entail on a day-to-day basis?…”

Section: For Reprint Orders Please Contact Reprints@future-sciencecommentioning

confidence: 99%

On the Bridge Over the Translational Valley of Death: Interview with Per I Arvidsson

Arvidsson

2017

Future Sci. OA

Self Cite

View full text Add to dashboard Cite

Per I Arvidsson speaks to Francesca Lake, Managing Editor: Per received his PhD in organic chemistry from Gothenburg University (Sweden) in 1999, where he continued as a lecturer for a short time. Following 2 years at the ETH Zurich (Switzerland) as a postdoctoral fellow, he went on to establish an independent research group at the Department of Biochemistry and Organic Chemistry at Uppsala University (Sweden). In 2006, he joined AstraZeneca R&D Södertälje (Sweden). After 1-year in-house training for future leaders in drug discovery and development, he became team leader in Medicinal Chemistry in 2007. In 2008, he was appointed Candidate Drug Delivery team leader with responsibility for preclinical drug discoveries in several CNS and pain projects. In 2010, he became Project Director at the innovative medicine unit for CNS & Pain research in Södertälje with responsibility from lead optimization to end of Phase II for projects in the neurodegeneration area. After joining AstraZeneca, he continued to pursue academic research as Adjunct Professor in bioorganic chemistry at the Department of Biochemistry and Organic Chemistry, Uppsala University (2007–2010), and the Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry, Uppsala University (2010–2013). In 2010, he was appointed honorary professor in Pharmacy and Pharmacology at the University of KwaZulu Natal (South Africa). In 2013, he was recruited to the Karolinska Institute in Stockholm as Director of Drug Discovery & Development, to build up the National Swedish infrastructure for Drug Discovery & Development at the Science for Life Laboratory (SciLifeLab). Since 2013, he has been a part-time research professor at the College of Health Science at the University of KwaZulu Natal. He is named inventor on over 15 patent applications, and coauthor to over 100 publications, two of which have won ‘most cited papers’ awards.

show abstract

Experiences in Academic and Industry Partnerships – Forging a Path to Translational Drug Discovery

Dolle

Barrault²,

Carragher³

et al. 2021

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Institutional Profile: the National Swedish Academic Drug Discovery & Development Platform at Scilifelab

Cited by 3 publications

References 34 publications

Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises

Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises

On the Bridge Over the Translational Valley of Death: Interview with Per I Arvidsson

Experiences in Academic and Industry Partnerships – Forging a Path to Translational Drug Discovery

Contact Info

Product

Resources

About